You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma

Article metrics

Article menu

Download PDFPDF

XML
Respiratory medicine
Research
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma

 

Online download statistics by month:

Online download statistics by month: January 2018 to April 2024

AbstractFullPdf
Jan 201816716113
Feb 20181721647
Mar 2018807921
Apr 201815815821
May 20181711717
Jun 2018696713
Jul 201855414
Aug 2018393513
Sep 2018201910
Oct 2018817913
Nov 2018747413
Dec 201862627
Jan 2019615911
Feb 2019575513
Mar 2019574119
Apr 2019301717
May 2019242116
Jun 2019131123
Jul 2019382611
Aug 201917138
Oct 2019331910
Nov 201929254
Dec 201922227
Jan 202027207
Feb 2020222216
Mar 2020282413
May 2020372614
Jun 2020272125
Jul 2020161613
Aug 2020322618
Sep 2020201610
Oct 2020302716
Nov 202029159
Dec 202021197
Jan 2021161416
Feb 2021888
Mar 2021292735
Apr 2021161513
May 2021242215
Jun 2021171512
Jul 2021343417
Aug 2021343317
Sep 2021242212
Oct 2021343229
Nov 2021212019
Dec 2021837131
Jan 2022493616
Feb 202236288
Mar 2022292720
Apr 2022241814
May 2022342824
Jun 20221997
Jul 202223199
Aug 2022332510
Sep 2022201916
Oct 2022241611
Nov 2022302410
Dec 202220184
Jan 2023413411
Feb 202325218
Mar 202336289
Apr 20239516
May 20237514
Jun 2023453922
Jul 2023262216
Aug 2023141217
Sep 202314815
Oct 202323176
Nov 202330124
Dec 202339316
Jan 2024322415
Feb 2024262410
Mar 2024311912
Apr 2024312416
Total29282556999